ClinicalTrials.Veeva

Menu
A

Allergy Research Canada, Inc. | Niagara Falls, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rocatinlimab
Upadacitinib
Baricitinib
Dupilumab
LY3009104
Ritlecitinib
Tapinarof
AMG 451
LP-003
JNJ-95597528

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 16 total trials

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis (READY-AD)

The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).

Active, not recruiting
Dermatitis, Atopic
Drug: JNJ-95597528
Drug: Placebo

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 2...

Active, not recruiting
Atopic Dermatitis
Drug: Vehicle Cream
Drug: Tapinarof cream, 1%

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneou...

Enrolling
Chronic Spontaneous Urticaria
Drug: Placebo - 100 mg
Drug: Ritlecitinib 50 mg

This study will evaluate the safety and efficacy of LP-003 for an increasing the amount of peanut protein that people with a peanut allergy can toler...

Begins enrollment this month
Peanut Allergies
Drug: Placebo Injection
Drug: LP-003 Injection

Trial sponsors

Amgen logo
AbbVie logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
E
Organon logo
Pfizer logo
L

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems